Abbott says market overestimating sales hit from new diabetes drugs
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Abbott (ABT) gains as 'strong' performance tops Q3 expectations
October 18, 2023 8:04 AM EDTAbbott (NYSE: ABT) shares are up more than 2% premarket Wednesday after the company reported earnings, topping consensus expectations.
The medical device company reported Q3 EPS of $1.14, $0.04 better than the analyst estimate of $1.10, while revenue for the quarter came in at $10.1 billion versus the consensus... More
